Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

Official Title: Phase II Study of Denosumab (NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma

This phase II trial studies how well denosumab works in treating patients with osteosarcoma that has come back (recurrent) or does not respond to treatment (refractory). Monoclonal antibodies, such as denosumab, may block tumor growth in different ways by targeting certain cells.

Walterhouse, David O., MD

Contact Information:

David Walterhouse, MD

Principal Investigator